George Simeon
George Simeon's purchase track record
How the stock did after each of George Simeon's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/16/2025 | CRSP | $51.50M | +30.3% | +3.2% | +10.6% |
| 3/27/2024 | NKTX | $20.00M | -46.1% | -57.6% | +9.0% |
| 12/16/2022 | DSGN | $7.57M | -26.0% | -38.1% | +14.5% |
| 4/28/2022 | NKTX | $20.00M | -26.1% | -31.9% | -11.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress. Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Design Therapeutics to Present at Cantor Fitzgerald Healthcare Conference. Design Therapeutics will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference. These events give companies a platform to engage with institutional investors and present their programs. The stock has traded within a 52-week range of $5.28 to $17.25, with analysts maintaining an average price target of $21.00.
Transaction History
| CRSP | ▲ Buy | Open Market | 6,510 | $339K | 7/16/2025 | View on chart |
| CRSP | ▲ Buy | Open Market | 22,319 | $1.2M | 7/16/2025 | View on chart |
| CRSP | ▲ Buy | Open Market | 960,983 | $50.0M | 7/16/2025 | View on chart |
| NKTX | ▲ Buy | Open Market | 1,548,341 | $15.5M | 3/27/2024 | View on chart |
| NKTX | ▲ Buy | Open Market | 451,659 | $4.5M | 3/27/2024 | View on chart |
| CRSP | ▲ Buy | Grant | 216,578 | $15.5M | 2/27/2024 | View on chart |
| CRSP | ▲ Buy | Grant | 63,177 | $4.5M | 2/27/2024 | View on chart |
| CRSP | ▲ Buy | Grant | 769,196 | $55.0M | 2/27/2024 | View on chart |
| DSGN | ▲ Buy | Open Market | 40,000 | $325K | 12/20/2022 | View on chart |
| DSGN | ▲ Buy | Open Market | 360,000 | $3.1M | 12/19/2022 | View on chart |
| DSGN | ▲ Buy | Open Market | 500,000 | $4.1M | 12/16/2022 | View on chart |
| NKTX | ▲ Buy | Open Market | 666,667 | $10.0M | 4/28/2022 | View on chart |
| NKTX | ▲ Buy | Open Market | 666,666 | $10.0M | 4/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
CRISPR Therapeutics to Share New Data at AHA and ACR 2026
CRISPR Therapeutics announced it will present late-breaking data at the American Heart Association and American College of Rheumatology conferences in 2026. These upcoming presentations are key events for the company, as they will provide new clinical insights into its treatments for heart and autoimmune conditions. The stock is currently trading near its 52-week low, making these data releases a significant factor for investors watching the company's progress.
CRISPR Therapeutics to Share New Data at AHA and ACR 2026. CRISPR Therapeutics announced it will present late-breaking data at the American Heart Association and American College of Rheumatology conferences in 2026. These upcoming presentations are key events for the company, as they will provide new clinical insights into its treatments for heart and autoimmune conditions. The stock is currently trading near its 52-week low, making these data releases a significant factor for investors watching the company's progress.